Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2003

View Archived Issues

New progesterone receptor modulators under investigation at Akzo Nobel

New prostanoid EP1 modulators in early development at GSK

Tropane-based chemokine CCR5 modulators newly developed at Pfizer

Sanofi-Synthelabo presents new bFGF antagonists for cancer and other disorders

Tanabe Seiyaku scientists design novel factor Xa inhibitors

Novel alpha4 integrin antagonists and their use reported by Uriach team

BMS researchers design novel IKK inhibitors for inflammatory and immune disorders

Aventis Pharma scientists design new glycogen phosphorylase inhibitors

Enrollment completed in final phase III trial for Entereg in postoperative ileus

Idec and Biogen complete merger

Toxicity studies for Inosine to pave way for IND filing

ECOG phase III trial of Rituxan reaches primary efficacy endpoint early

HIVA.MVA trials commence in South Africa and Switzerland

Abbott transfers joint diabetes collaboration rights to Karo Bio

Protocol finalized for Mycograb trial

Plexxikon research supports drug discovery for phosphodiesterase targets

Predix and RRD team up to expedite development of PRX-00023

New review date set for Estorra NDA

4SC and Switch Biotech enter dermatological drug discovery partnership

Tanox and Wyeth enter osteoporosis development agreement

TopoTarget initiates phase I U.K. study of PXD-101

ViaCell acquires Kourion Therapeutics

Silver-based antimicrobial agent may help prevent the spread of SARS

Kissei preparing to license two of its products

LY-156735 is safe and well tolerated in healthy volunteers

Focus on drug therapy for autism

Improved quality of life found with CTLA4Ig and methotrexate in RA patients

Therapeutic benefits of intraurethral botulinum toxin type A in urinary tract dysfunction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...